Literature DB >> 17179741

Activation of serum response element by D2 dopamine receptor is governed by Gbetagamma-mediated MAPK and Rho pathways and regulated by RGS proteins.

Guyu Ho1, Yuren Wang, Philip G Jones, Kathleen H Young.   

Abstract

In this study, we investigated the activation of the serum response element (SRE) by the D2 dopamine receptor (D2R) agonist quinpirole. Stimulation of CHO cells expressing the D2R by quinpirol evoked a dose-dependent SRE activation, which was completely blocked by overnight treatment of pertussis toxin or by co-expression of the beta-adrenergic receptor kinase C-terminus, implicating the involvement of Galpha(i )and Gbetagamma in the signal transduction. Furthermore, using MEK inhibitors and dominant negative mutants of RhoA, Rac1, and Cdc42, we showed that the Gbetagamma-mediated activation of the SRE in CHO cells utilizes both MAPK and Rho pathways. Expression of either regulator of G protein signaling 2 or 4 (RGS2 or RGS4) proteins significantly attenuated the quinpirole-induced SRE activation. These results delineate the signaling pathways which couple D2 receptor to the transcriptional activation of SRE and demonstrate a modulatory role for RGS proteins in these processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17179741     DOI: 10.1159/000098097

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  2 in total

1.  Regulator of G protein signaling-4 controls fatty acid and glucose homeostasis.

Authors:  Irena Iankova; Carine Chavey; Cyrielle Clapé; Claude Colomer; Nathalie C Guérineau; Nicolas Grillet; Jean-François Brunet; Jean-Sébastien Annicotte; Lluis Fajas
Journal:  Endocrinology       Date:  2008-07-17       Impact factor: 4.736

2.  Hypoxic induction of the regulator of G-protein signalling 4 gene is mediated by the hypoxia-inducible factor pathway.

Authors:  Sam W Z Olechnowicz; Anthony O Fedele; Daniel J Peet
Journal:  PLoS One       Date:  2012-09-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.